Whole genome and exome sequencing of pNENs to investigate PRRT response

A new study looked at the DNA of pancreatic neuroendocrine tumours (pNETs) to see whether genetic changes could explain why some patients respond better to peptide receptor radionuclide therapy (PRRT) than others. For people with Multiple Endocrine Neoplasia type 1 (MEN1), the findings are important because MEN1 was one of the most common gene changes found, occurring in about one-third of the tumours studied. However, researchers found that having a MEN1-related tumour did not predict how well a patient would respond to PRRT. Overall, PRRT controlled tumour growth in most patients, and the study found no major DNA changes caused by the treatment itself. The results suggest that while MEN1 plays a key role in the development of many pancreatic neuroendocrine tumours, other factors are likely to determine how well PRRT works. Further research is needed to identify better markers that can help predict treatment response and guide personalised care for people with MEN1-associated pNETs.

Emma Boehm, et al; Whole genome and exome sequencing of pancreatic neuroendocrine tumours to investigate PRRT response. Endocr Relat Cancer 1 August 2026; 33 (8): e260207. https://doi.org/10.1530/ERC-26-0207
.